Current Research Failings

Sixty years of research, 2000 medical papers and tremendous global effort on Motor Neuron Disease has not resulted in a solution or treatment that can provide some hope the people living with this disease. Similar is the scenario for other NDs.

The pertinent questions we are asking are :

  1. Why isn’t the current thinking on these diseases working?
  2. Why have we not seen the real translation of these approaches used in treating MND?
  3. Are we looking at the wrong targets?
  4. Will a more holistic approach on genome, microbiome and proteome machinery answer relevant questions that may guide us with treatments and diagnosing these diseases earlier?

The problem is:

  • Current medical research into MND and other NDs is possibly looking in the wrong targets
  • Greater focus (>60%) of research focus on genetic triggers of MND, where only 5% of MND sufferers have a genetic predisposition.
  • Immense focus on visualizing single entity for diseases that are multifactorial, as a consequence of which 95% of the MND and ND sufferers only have an option to manage the disease-with no strategies for functional cure.
  • Serious lack of sharing of information as collaboration has become harder to facilitate.
  • No one really knows what the problem is – science is lost on the issue

Let’s put this disease in perspective:

Motor Neuron Disease is the most debilitating of all neurodegenerative diseases, as physical degeneration is rapid whilst the patient’s mental capacity remains intact right until the end. They are fully aware of their impending death and they suffer each day as they lose mobility. Watching and caring for a loved one with Motor Neuron is horrendous.

Every day 2 Australians pass away from MND

Every day 2 Australians are diagnosed with MND

The average life expectancy is 27 months from diagnosis

The cost burden of the disease to pay for management, care and drugs is $1.1 million per person which is huge!

What about current treatments?

There are several medical treatments currently in the market, however none of them are directed to curative strategies or halting the progression. All current drugs have minimal and transitory symptomatic benefit to the patient, despite trials which will indicate otherwise. We know this from our own experience as our founder, who is afflicted with MND, trialled all available treatments with no success leading to further deterioration.  Secondly, we have analysed international patient results databases that track the results of each patient taking each of these available medications. Surprisingly, they also show no improvement, and it is widely believed that the current medications are ineffective, as they are guided to treat one entity. Our multi-entity approach is a unique one that will provide avenues to treat MNDs and other NDs more holistically.

What about drug trials?

55 drug trials since 1970

32 trials have failed

17 trials are on-going

6 trials have ‘succeeded’ by passing the relevant phase and are on on-going

Looking at current drugs that target single entity is not an option.

New drugs are needed that can target a pathway to a single gene

We need a change of thinking in the way we visualize MND and NDs

Iggy Get out was born with a different ideology, based on collaboration and adopting an outside the box approach to Neurodegenerative Diseases.  We are relentlessly committed to helping solve the mystery and find a treatment of Neurodegeneration diseases such as MND, ALS, Alzheimer’s, Parkinson’s disease, and Multiple sclerosis, and other related problems increasingly effecting people of all ages.

DONATE

Help us solve the mystery and find a treatment for Neurodegeneration diseases.

FOLLOW

Stay up to date with our latest research findings, connect with our community and find out about our up-coming events.

EVENTS

Come and support Iggy Get Out at one of our legendary events.